hc1 Launches HerCare for early detection of anemia in pregnant women

WT default author logo
Women's Tabloid News Desk

hc1, a healthcare technology company, has launched HerCare, a new module within its MyBloodHealth platform, aimed at addressing anemia risks in pregnancy. The module identifies insights from lab data to proactively treat expectant mothers who have anemia, a critical risk factor linked to complications such as preeclampsia, pre-term birth, and postpartum depression. The launch aims to provide real-time clinical decision support to obstetrics teams to improve maternal health outcomes. HerCare is being rolled out initially to existing MyBloodHealth customers, with plans for wider availability later in 2025. This initiative by hc1 seeks to reduce preventable pregnancy complications by enabling early risk detection and personalized care for pregnant women.

“At hc1, we are committed to improving women’s care, and our team created HerCare to prevent complications during and after pregnancy,” said hc1 CEO, Founder, and Chairman Bradley Bostic. “HerCare identifies insights in lab data to proactively treat expectant mothers who have anemia, a critical risk factor in pregnancy. By leveraging our MyBloodHealth platform, hc1 is collaborating with leading healthcare organizations to close this critical gap in obstetric care by giving clinicians the tools they need to make informed, often life-saving decisions.”

With ambitions to expand its availability to hospital systems and obstetrics practices in late 2025, the business is first introducing HerCare to existing MyBloodHealth clients on a restricted basis. According to HC1, the HerCare module uses three main strategies to lessen avoidable pregnancy complications:

Early risk detection: Using real-time lab and clinical data monitoring to identify patients who are at risk.

Personalised care: Providing specific information to help inform choices that improve patient safety.

Clinical decision support: Giving medical professionals evidence-based suggestions for prompt actions.

The HerCare module embodies HC1’s overarching goal of uncovering critical health information concealed in laboratory data.  To find actionable insights and hidden risk flags, the company’s MyBloodHealth platform uses superior data management, analytics, and AI-powered process automation.

Share:

Related Insights

Lisa Gelobter appointed New York City’s Chief Technology Officer by Mayor Zohran Mamdani

ChatGPShe brings senior women hospitality leaders together to shape AI-driven leadership

Women’s Health, Sports & Performance Institute launches in Boston with over $50 million backing

Netflix promotes Elizabeth Stone to Chief Product and Technology Officer

Pasito secures $21 million Series A to expand AI-driven benefits automation platform

AstraZeneca commits $15 billion investment in China through 2030 to expand R&D and manufacturing

Melio launches Agent Mel to simplify financial decision-making for small businesses

WellTheory launches postpartum program for women managing autoimmune symptoms after childbirth